Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 278

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 278
---
cingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as Chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its Chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France. 121 Dr. Kfir Molakandov PhD, Vice President Research and Development Dr. Kfir Molakandovhas served as Vice President and Head of Research and Development at Kadimastem since January 2018, and he was previously a researcher at Kadimastem from January 2011 until December 2017. He received his B.A, M.Sc. in Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from Tel Aviv University, Israel. Prof. Ariel Revel, MD, Director of Medical Affairs Professor Ariel Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served as a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a Professor of Medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009, and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April 2017 until April 2024, he served at the Assaf Harofeh Medical Center. On April 2017 until April 2021, he served as a Professor at Assaf Harofeh Medical Center. He began his medical career in August 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May 2017. Professor Revel received his PhD from Tel -AvivUniversity and an MD degree from the Hebrew University of Jerusalem, Israel. Dr. Eric Konofal, MD, Ph.D., Head of DOXA program Dr. Eric Konofal has served as NLS’s Chief Scientific Officer since February 2021 and as its Interim Chief Medical Officer since January 2024. Dr. Kon